MHRA
Regulating Medicines and Medical Devices

MHRA
151 Buckingham Palace Road
London SW1W 9SZ
United Kingdom

mhra.gov.uk

Mrs E Lawrie
CANCER RESEARCH UK & UNIV. COLL. LONDON CANCER TRIALS CENTRE
HAEMATOLOGY TRIALS GROUP
90 TOTTENHAM COURT ROAD
LONDON
W1T 4TJ
UNITED KINGDOM

13/03/2017

Dear Mrs E Lawrie

THE MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS 2004 S.I. 2004/1031

Our Reference:	20363/0273/001-0018
Eudract Number:	2009-012717-22
Product:	rituximab
Protocol number:	UCL/08/0167
Substantial Amendment Code Number:	Code Number: Substantial Amendment (Protocol v9) MHRA
Version: 9.0	
Date: 2017/02/22	

NOTICE OF ACCEPTANCE OF AMENDMENT

I am writing to inform you that the Licensing Authority accepts the proposed amendment to your clinical trial authorisation (CTA), received on 22/02/2017.

This amendment may therefore be made.

You are reminded that where it is appropriate, the Ethics Committee should also be notified of amendments.

Yours sincerely,

Clinical Trials Unit
MHRA

RECEIVED 20 MAR 2017